Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis

Next Previous
Trial Profile

A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lebrikizumab (Primary) ; Diphtheria vaccine; Meningococcal vaccine groups A B C Y W-135 conjugate; Tetanus vaccine
  • Indications Atopic dermatitis
  • Focus Pharmacodynamics; Registrational
  • Acronyms ADopt-VA
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 20 Oct 2022 Status changed from active, no longer recruiting to completed.
  • 06 Sep 2022 Planned End Date changed from 12 Oct 2022 to 28 Oct 2022.
  • 08 Aug 2022 Planned End Date changed from 28 Oct 2022 to 12 Oct 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top